Loading IOVA detail
Loading ticker data...
Loading IOVA detail
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells.
It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M. D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017.
Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
Chart data unavailable
Iovance Biotherapeutics' most important product is generating rapidly growing sales. Between approvals in other countries and label expansions, it could maintain its momentum for a while.
Aberdeen Group plc raised its stake in shares of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) by 25.1% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 759,522 shares of the biotechnology company's stock after buying an additional 152,312 shares during
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA - Get Free Report)'s share price passed below its 50-day moving average during trading on Monday. The stock has a 50-day moving average of $3.42 and traded as low as $3.28. Iovance Biotherapeutics shares last traded at $3.30, with a volume of 9,777,900 shares traded. Wall Street Analyst Weigh In
Iovance Biotherapeutics is positioned for multi-year growth, with Amtagvi sales and pipeline momentum accelerating despite recent share price volatility. Real-world Amtagvi data shows a 44% ORR and 73% disease control, outperforming pivotal trial results and driving increased physician adoption in less heavily pretreated patients. IOVA's pipeline catalysts include pivotal NSCLC data in 2024, sarcoma expansion with efficient trial design, and global regulatory reviews, supporting a blockbuster potential beyond melanoma.
Shares of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA - Get Free Report) have been assigned an average recommendation of "Hold" from the twelve brokerages that are presently covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, four have issued a hold recommendation and six have issued a buy
Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock?
SAN CARLOS, Calif., March 20, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on March 19, 2026 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 3,400 shares of Iovance's common stock to one new, non-executive employee.
Cancer remains one of the greatest medical challenges for biotechnology firms, even as the oncology medicine market is expected to surge to $366 billion in the next eight years. Companies often take a niche approach, developing medicines aiming to address a specific type of cancer with particular dedicated mechanisms.
Iovance Biotherapeutics, Inc. (IOVA) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Iovance Biotherapeutics Inc. (NASDAQ: IOVA) stock is trading higher on Friday, with no news to justify the movement.
Shares of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA - Get Free Report) reached a new 52-week high during trading on Thursday after UBS Group raised their price target on the stock from $2.00 to $4.00. UBS Group currently has a neutral rating on the stock. Iovance Biotherapeutics traded as high as $4.38 and last traded at $4.29,
Iovance Biotherapeutics' most important product has strong momentum right now. However, the company faces significant challenges that make the stock risky.
Iovance Biotherapeutics (IOVA) remains a high-risk, high-reward play, with lifileucel (Amtagvi) now approved for advanced melanoma and 2025 company revenues of $264m. IOVA faces persistent losses, a precarious cash runway, and intense competition, but real-world efficacy and expanding treatment center networks support cautious optimism. Key 2026–2027 catalysts include potential approvals in NSCLC and first-line melanoma, with blockbuster ambitions hinging on successful clinical and regulatory milestones.
SAN CARLOS, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following upcoming conferences:
A relative unknown, if you don't watch the biotherapeutics industry, Iovance Biotherapeutics ( NASDAQ:IOVA ) surged 43% in the past week after reporting Q4 2025 earnings on February 24, pushing Reddit sentiment to 86 out of 100.
